FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

The CDC already recommends the RSV shot for all adults 75 and older and for people 60 and older who have health conditions that increase their risk of severe RSV. It also recommends the shot during ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Kennedy selected a new team of medical professionals and scientists who are highly qualified and dedicated to public health.

More than 14 million children around the world have not received a single dose of any vaccine, according to new data from the ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory ...

H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following ...

The diagnosis was confirmed through rapid testing after the Coconino County resident was admitted to Flagstaff Medical Center. Pneumonic plague is the only form of the plague that can be transmitted ...